Sarepta therapeutics announces approval in japan of elevidys, a gene therapy to treat duchenne muscular dystrophy

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that the japanese ministry of health, labour, and welfare (mhlw) has approved elevidys (delandistrogene moxeparvovec) for the treatment of duchenne muscular dystrophy (dmd) under the conditional and time-limited approval pathway in japan. elevidys is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo.
SRPT Ratings Summary
SRPT Quant Ranking